UTI Asset Management Company Limited has informed the Exchange regarding Board meeting held on July 24, 2025.
UTIAMC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Smallcap 250 and 3.1 pts less than its Asset Management Company peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
UTI AMC's Board, on July 24, 2025, approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, profit after tax rose to ₹216.13 crore from ₹185.81 crore in Q1 FY25 (about 16% growth), while revenue from operations grew to ₹436.88 crore from ₹386.56 crore. Consolidated profit after tax dipped to ₹253.86 crore from ₹274.30 crore in Q1 FY25, with revenue at ₹546.89 crore versus ₹529.22 crore. The Board also approved a ₹45 crore unsecured working capital loan to its wholly-owned subsidiary UTI Alternatives Private Limited (UTI APL), at 1-year SBI MCLR interest rate, repayable by March 31, 2028. Statutory auditor B S R & Co. LLP issued an unqualified limited review report on both sets of results.
Standalone earnings show healthy growth driven by sale of services and fair value gains, supporting a positive near-term view; however, the slight dip in consolidated PAT and absence of fresh dividend announcement may limit upside excitement. The ₹45 crore inter-corporate loan to a wholly-owned subsidiary is a routine related-party transaction at arm's length and is unlikely to materially affect shareholders.